Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer, Jean-Pierre; Sambrook, Philip; Reid, David Met al.
[en] Objective. Long-term glucocorticoid use is accompanied by rapid bone loss; however, early treatment with bisphosphonates prevents bone loss and reduces fracture risk. The aim of this study was to examine the effects of two bisphosphonates, i.v. zoledronic acid (ZOL) versus oral risedronate (RIS), on bone turnover markers (BTMs) in subjects with glucocorticoid-induced osteoporosis (GIO).Methods. Patients were randomly stratified according to the duration of pre-study glucocorticoid therapy [prevention subpopulation (ZOL, n = 144; RIS, n = 144) </=3 months, treatment subpopulation (ZOL, n = 272; RIS, n = 273) >3 months]. Changes in beta-C-terminal telopeptides of type 1 collagen (beta-CTx), N-terminal telopeptide of type I collagen (NTx), procollagen type 1 N-terminal propeptide (P1NP) and bone-specific alkaline phosphatase (BSAP) from baseline were measured on day 10 and months 3, 6 and 12.Results. At most time points, there were significantly greater reductions (P < 0.05) in the concentrations of serum beta-CTx, P1NP and BSAP and urine NTx in subjects on ZOL compared with RIS in both males and females of the treatment and prevention subpopulations. In pre- and post-menopausal women, there were significantly greater reductions in the concentrations of BTMs with ZOL compared with RIS. At 12 months, ZOL had significantly greater reductions compared with RIS (P < 0.05) for beta-CTx, P1NP, BSAP and NTx levels, independent of glucocorticoid dose.Conclusions. Once-yearly i.v. infusion of ZOL 5 mg was well tolerated in different subgroups of GIO patients. ZOL was non-inferior to RIS and even superior to RIS in the response of BTMs in GIO patients.Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00100620.
Disciplines :
General & internal medicine
Author, co-author :
Devogelaer, Jean-Pierre
Sambrook, Philip
Reid, David M
Goemaere, Stefan
Ish-Shalom, Sophia
COLLETTE, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Su, Guoqin
Bucci-Rechtweg, Christina
Papanastasiou, Philemon
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Van Staa TP, Abenhaim L, Cooper C et al. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000;9:359-66.
Doga M, Mazziotti G, Bonadonna S et al. Prevention and treatment of glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008;31(Suppl 7):53-8.
Devogelaer JP. Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am 2006;32:733-57.
McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008;20:131-7.
Hayashi K, Yamamoto M, Murakawa Y et al. Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density. Osteoporos Int 2009;20: 1889-94.
Angeli A, Guglielmi G, Dovio A et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006;39:253-9.
Naganathan V, Jones G, Nash P et al. Vertebral fracture risk with long term corticosteroids: prevalence, relationship to age, bone density and corticosteroid use. Arch Intern Med 2000;160:2917-22.
Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology 2002;41:1088-94.
Hart SS, Green B. Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad Med J 2002;78:242-3.
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44:1496-503.
Homik JE, Cranney A, Shea B et al. A meta analysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999;26:1148-57.
Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving GC: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44:202-11.
Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000;15:1006-13.
Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9.
Sambrook PN, Kotowicz M, Nash P et al. Prevention and treatment of glucocorticoid induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium and alendronate plus calcium. J Bone Miner Res 2003;18: 919-24.
Craig SJ, Youssef PP, Vaile JH et al. Intravenous zoledronate and oral alendronate in patients with a low trauma fracture-experience from an osteoporosis clinic. Intern Med J 2010;41:139-215.
Seeman E, Compston J, Adachi J et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 2007;18:711-9.
Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
Lyles KW, Coló n-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
Boonen S, Sellmeyer DE, Lippuner K et al. Renal safety of annual zoledronic acid infusions in osteoporotic post-menopausal women. Kidney Int 2008;74: 641-8.
Recknor C. Zoledronic acid for prevention and treatment of osteoporosis. Expert Opin Pharmacother 2011;12: 807-15.
Jansen JP, Bergman GJ, Huels J et al. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 2011;40: 275-84.
Akehurst R, Brereton N, Ariely R et al. The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fracture: evidence from Finland, Norway and the Netherlands. J Med Econ 2011;14:53-64.
Bergmann P, Body JJ, Boonen S et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis. Int J Clin Pract 2009;63: 19-26.
Reginster JY, Collette J, Neuprez A et al. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008;42: 832-36.
Minisola S, Del Fiacco R, Piemonte S et al. Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008;31:28-32.
Reid DM, Devogelaer J-P, Saag K et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63.
Jaffe M. Ueber den niederschlag, welchen picrinsaure in normalen harn erzeugt und eine neue reaction des kreatinins. Hoppe Seylers Z Physiol Chem 1886;10: 391-400.
Foster-Swanson A, Swartzentruber M, Roberts P et al. Reference interval studies of the rate-blanked creatinine/ Jaffe method on BM/Hitachi systems in six US laboratories [abstract]. Clin Chem 1994;40:1057.
Gough AK, Lilley J, Eyre S et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344: 23-7.
Pearce G, Ryan PFJ, Delmas PD et al. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998;37:292-9.
Orwoll ES, Miller PD, Adachi JD et al. Efficacy and safety of a once-yearly IV infusion of zoledronic acid 5mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010;25:2239-50.
MacDonald AG, Birkinshaw G, Durham B et al. Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 36:50-3.
McClung M, Miller P, Recknor C et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009;114:999-1007.
Sornay-Rendu E, Munoz F, Garnero P et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20:1813-9.
Wainwright SA, Marshall LM, Ensrud KE et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90:2787-93.
Drake WM, Kendler DL, Rosen CJ et al. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 2003;88:5759-65.
Lenora J, Ivaska KK, Obrant KJ et al. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007;18:1297-305.
Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 2000;15:1398-404.
Garnero P, Munoz F, Sornay-Rendu E et al. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007;40: 716-22.
Eastell R, Black DM, Boonen S et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 2009;94:3215-25.
Boonen S, Black MD, Colon-Emeric SC et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292-9.
McClung M, Recker R, Miller P et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41: 122-8.
Saag K, Lindsay R, Kriegman A et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40: 1238-43.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
